CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D053201: Urinary Bladder, Overactive NIH

(Synonyms: Urinary Bladder, O, Urinary Bladder, Ov, Urinary Bladder, Overactiv, Urinary Bladder, Overactive)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug329 BAY1817080 Wiki 1.00
drug1785 Moxifloxacin Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D004715 Endometriosis NIH 0.71

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0030127 Endometriosis HPO 0.71

There is one clinical trial.

Clinical Trials


1 Randomized, Single-blind, Double-dummy, 4-fold Cross-over, Placebo- and Active-controlled Study to Investigate the Influence of BAY 1817080 on the QTc Interval in Healthy Male and Female Participants (TQT Study)

In this study, researchers want to find whether the study drug BAY1817080 has an effect on the electrocardiogram (ECG). 40 healthy male or female participants with the age of 18 to 65 years will be enrolled into this study. The ECG of the participants will be monitored closely by the researchers to detect any change after intake of the study medication.

NCT04423744 Cough Endometriosis Overactive Bladder Drug: BAY1817080 Drug: Moxifloxacin Drug: Placebo
MeSH:Urinary Bladder, Overactive Endometriosis
HPO:Endometriosis

Primary Outcomes

Measure: Time-matched, placebo-corrected change from baseline of the individually corrected QT interval after multiple oral doses of BAY1817080 therapeutic dose

Time: Baseline and Day 3

Measure: Time-matched, placebo-corrected change from baseline of the individually corrected QT interval after multiple oral doses of BAY1817080 supra-therapeutic dose

Time: Baseline and Day 3

Secondary Outcomes

Measure: Time-matched, placebo-corrected change from baseline of the individually corrected QT interval after a single oral dose of moxifloxacin

Time: Baseline and Day 3

Measure: Time-matched, placebo-corrected change from baseline of the QT interval corrected according to Fridericia (QTcF) and Bazett (QTcB) after multiple oral doses of BAY1817080 therapeutic or supra-therapeutic dose

Time: Baseline and Day 3

Measure: Time-matched, placebo-corrected change from baseline of the QT interval corrected according to Fridericia (QTcF) and Bazett (QTcB) after a single oral dose of moxifloxacin

Time: Baseline and Day 3

Description: Area under the concentration vs. time curve from zero to 24 hours after multiple doses

Measure: AUC(0-24)md after multiple oral doses of BAY1817080 therapeutic or supra-therapeutic dose

Time: Predose and up to 24 hours after last dose of BAY1817080 at Day 3

Description: Area under the concentration vs. time curve from zero to infinity after single dose

Measure: AUC after a single oral dose of moxifloxacin

Time: Predose and up to 24 hours after single dose of moxifloxacin at Day 3

Description: Maximum observed drug concentration in measured matrix after multiple doses

Measure: Cmax,md after multiple oral doses of BAY1817080 therapeutic or supra-therapeutic dose

Time: Up to 24 hours after last dose of BAY1817080 at Day 3

Description: Maximum observed drug concentration in measured matrix after single dose

Measure: Cmax after a single oral dose of moxifloxacin

Time: Up to 24 hours after single dose of moxifloxacin at Day 3

Measure: Incidences of treatment-emergent adverse events (TEAEs) after BAY1817080 therapeutic or supra-therapeutic dose

Time: From the start of BAY1817080 administration until 7 days after last dose, assessed up to 10 days


HPO Nodes